Value of liver stiffness measurement in the diagnosis of liver fibrosis degree in HBeAg-positive patients with chronic HBV infection

Liu Na; Li ChunXia; Dong Bing; Zhou LuLu; Zhang RuiQin; Zhao YingRen; He YingLi; Xu GuangHua

doi:10.3969/j.issn.1001-5256.2019.06.016

Volume 35 Issue 6

Jun. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(6): 1262-1265

PDF( 2101 KB)

Value of liver stiffness measurement in the diagnosis of liver fibrosis degree in HBeAg-positive patients with chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2019.06.016

Department of Infectious Diseases, Affiliated Hospital of Yan'an University

Research funding:

Received Date: 2019-01-14
Published Date: 2019-06-20

Abstract

Abstract

To investigate the value of liver stiffness measurement (LSM) in the diagnosis of liver fibrosis degree in HBeAg-positive patients with chronic HBV infection. Methods A retrospective analysis was performed for the clinical data of 330 HBeAg-positive patients with chronic HBV infection who were hospitalized in Affiliated Hospital of Yan'an University from October 2013 to August 2018 and underwent liver biopsy, and according to liver pathological results, these patients were divided into mild liver fibrosis group (F0-F1) and significant liver fibrosis group (F2-F4) . The t-test or the Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data between two groups. Univariate and multivariate analyses were performed to screen out the indices for the diagnosis of significant liver fibrosis, and the receiver operating characteristic (ROC) curve was plotted for these indices to evaluate their value in the diagnosis of significant liver fibrosis. Results Of all 330 patients, 245 had mild liver fibrosis and 85 had significant liver fibrosis. There were significant differences between the two groups in HBV DNA, HBsAg, HBeAg, HBcAb, alanine aminotransferase, aspartate aminotransferase, total bilirubin, and LSM (all P < 0. 05) . The multivariate analysis showed that HBsAg and LSM were independent risk factors for significant liver fibrosis (both P < 0. 05) . The ROC curve analysis showed that only LSM had a diagnostic value, with an area under the ROC curve of 0. 744 (95% confidence interval: 0. 680-0. 808) . At the optimal cut-off value of6. 15 kPa, LSM had a sensitivity of 62. 4%, a specificity of 76. 3%, an accuracy of 72. 1%, a positive predictive value of 72. 5%, and a negative predictive value of 67. 0% in predicting significant liver fibrosis. Conclusion LSM has a good value in predicting significant liver fibrosis in HBeAg-positive patients with chronic HBV infection.
- hepatitis B, chronic,
- hepatitis B e antigens,
- liver cirrhosis,
- liver stiffness measurement,
- diagnosis

FullText(HTML)

References(20)

References

[1]SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al.Estimations of worldwide prevalence of chronic hepatitis B virus infection:A systematic review of data published between 1965 and2013[J].Lancet, 2015, 386 (10003) :1546-1555.

[2]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[3]TERRAULT NA, LOK ASF, McMAHON BJ, et al.Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J].Hepatology, 2018, 67 (4) :1560-1599.

[4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[5]CAVIGLIA GP, ABATE ML, PELLICANO R, et al.Chronic hepatitis B therapy:Available drugs and treatment guidelines[J].Minerva Gastroenterol Dietol, 2015, 61 (2) :61-70.

[6]DENG GH, WANG ZL, WANG YM, et al.Dynamic determination and analysis of serum virus load in patients with chronic HBV infection[J].World Chin J Dig, 2004, 12 (4) :862-865. (in Chinese) 邓国宏, 王宗笠, 王宇明, 等.慢性HBV感染者血清病毒动力学的检测及分析[J].世界华人消化杂志, 2004, 12 (4) :862-865.

[7]SHARAIHA RZ, KUMTA NA, SAUMOY M, et al.Endoscopic sleeve gastroplasty significantly reduces body mass index and metabolic complications in obese patients[J].Clin Gastroenterol Hepatol, 2017, 15 (4) :504-510.

[8]OU H, CAI S, LIU Y, et al.A noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B[J].Therap Adv Gastroenterol, 2017, 10 (2) :207-217.

[9]PENG J, CAI S, YU T, et al.Aspartate aminotransferase to platelet ratio index-a reliable predictor of therapeutic efficacy and improvement of Ishak score in chronic hepatitis B patients treated with nucleoside analogues[J].Scand J Clin Lab Invest, 2016, 76 (2) :133-142.

[10]BRAVO AA, SHETH SG, CHOPRA S.Liver biopsy[J].N Engl J Med, 2001, 344 (7) :495-500.

[11]BEDOSSA P, POYNARD T.An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group[J].Hepatology, 1996, 24 (2) :289-293.

[12]CASTERA L, FORNS X, ALBERTI A.Non-invasive evaluation of liver fibrosis using transient elastography[J].J Hepatol, 2008, 48 (5) :835-847.

[13]European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH clinical practice guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol, 2015, 63 (1) :237-264.

[14]CAO FM, ZHANG ZR, WANG X.The study correlation between liver stiffness and pathological staging of liver biopsy in patients with chronic hepatitis B by Fibroscan[J].Hebei Medicine, 2018, 24 (7) :1223-1226. (in Chinese) 曹发明, 张照如, 王翔.Fibroscan测定慢性乙型肝炎患者肝硬度值与肝组织活检病理学分期的相关性研究[J].河北医学, 2018, 24 (7) :1223-1226.

[15] DUAN WJ, WANG XM, WANG Y, et al.Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients[J].Chin J Exp Clin Virol, 2018, 32 (4) :399-402. (in Chinese) 段维佳, 王晓明, 王宇, 等.FibroTouch和FibroScan检测评估慢性乙型肝炎患者肝纤维化程度的诊断价值[J].中华实验和临床病毒学杂志, 2018, 32 (4) :399-402.

[16]TAN YW, ZHOU XB, YE Y, et al.Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase[J].World JGastroenterol, 2017, 23 (31) :5746-5754.

[17]ZHANG XY, QIAN J, HOU W, et al.Clinical value of diagnosing hepatic fibrosis by Mohamadnejad model and FibroScan in the HBe Ag negative chronic hepatitis B virus carriers[J].Chin J Exp Clin Virol, 2018, 32 (1) :70-74. (in Chinese) 张孝盈, 钱静, 侯伟, 等.利用Mohamadnejad模型和FibroScan诊断HBe Ag阴性慢性HBV携带者肝纤维化的临床价值[J].中华实验和临床病毒学杂志, 2018, 32 (1) :70-74.

[18]CHAN AO, YUEN MF, LAM CM, et al.Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong[J].Aliment Pharmacol Ther, 2004, 19 (4) :401-406.

[19]LIN CL, KAO JH.Review article:The prevention of hepatitis B-related hepatocellular carcinoma[J].Aliment Pharmacol T-her, 2018, 48 (1) :5-14.

[20]ZHOU JL, WU XN, SUN YM, et al.Progress in clinical studies of noninvasive early diagnosis of liver fibrosis and cirrhosis[J].JClin Hepatol, 2018, 34 (8) :1674-1677. (in Chinese) 周家玲, 吴晓宁, 孙亚朦, 等.ALT水平对乙型肝炎肝硬化患者肝脏硬度值的影响[J].临床肝胆病杂志, 2018, 34 (8) :1674-1677.

Relative Articles

[1]	Jinqiu YANG, Wenxia ZHAO, Cheng ZHOU, Tong LIU. Risk factors for the development of advanced liver fibrosis in nonalcoholic fatty liver disease and establishment of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(8): 1579-1584. doi: 10.12449/JCH240812
[2]	Shunxiao ZHANG, Sheng ZHANG, Yan ZHANG, Yuanyuan LI, Yue CHEN, Mingyu SUN. Influencing factors for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus[J]. Journal of Clinical Hepatology, 2023, 39(5): 1081-1088. doi: 10.3969/j.issn.1001-5256.2023.05.013
[3]	Yujuan ZHANG, Xiqiao ZHOU. Research advances in lean nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(12): 2914-2919. doi: 10.3969/j.issn.1001-5256.2023.12.024
[4]	Sarula BAO, Xiaoxu DU, Hongyan GE. Value of Helicobacter pylori infection combined with traditional risk factors in predicting the risk of metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(6): 1318-1324. doi: 10.3969/j.issn.1001-5256.2023.06.011
[5]	Yifu YUAN, Qin CAO, Yuanye JIANG. Association of dietary behavior with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(2): 401-407. doi: 10.3969/j.issn.1001-5256.2023.02.024
[6]	Cheng ZHOU, Ran JIA, Jingjing WEI, Chenlu ZHAO, Dongfang SHANG, Wenxia ZHAO. Risk factors for cognitive impairment associated with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2022, 38(11): 2592-2595. doi: 10.3969/j.issn.1001-5256.2022.11.031
[7]	Ling QING, Weiqiang HUANG, Xiaohe LI, Feng CHEN, Yingxia LIU. Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2075-2080. doi: 10.3969/j.issn.1001-5256.2021.09.015
[8]	He CHEN, Juanjuan FU, Li LI, Guangde YANG, Xiucheng PAN. Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(3): 556-559. doi: 10.3969/j.issn.1001-5256.2021.03.011
[9]	Yangyang LI, Zhengyuan XIE. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 452-457. doi: 10.3969/j.issn.1001-5256.2021.02.043
[10]	Tian TIAN, Wenwei HU, Xue LI, Jie WU, Dan ZHANG, Changzheng LI. Association between thyroxine level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2357-2363. doi: 10.3969/j.issn.1001-5256.2021.10.020
[11]	Cong TONG, Yanian LI, Da GU, Xiang'an ZHAO, Xiaoxing XIANG. The association between obesity measurement indices and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2465-2468. doi: 10.3969/j.issn.1001-5256.2021.10.044
[12]	Dongxu WANG, Chuan XING, Bo LYU, Han ZHAO, Bing HE. Risk factors for polycystic ovary syndrome with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2474-2477. doi: 10.3969/j.issn.1001-5256.2021.10.046
[13]	Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024
[14]	Yao ChengZi, Liu ZiZhen, Feng Gong, He Na, Mi Man. Risk factors for childhood nonalcoholic fatty liver disease and related prevention and management strategies[J]. Journal of Clinical Hepatology, 2020, 36(7): 1623-1626. doi: 10.3969/j.issn.1001-5256.2020.07.038
[15]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[16]	Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
[17]	Huang ZhiPeng, Jiang JianJia, Huang ZiCheng, Guo GuiYuan, Zhou APei, Liu XiaoQiang. Risk factors of nonalcoholic fatty liver disease with a normal visceral adipose tissue area[J]. Journal of Clinical Hepatology, 2019, 35(5): 1061-1064. doi: 10.3969/j.issn.1001-5256.2019.05.025
[18]	Ding YuPing, Li Hai, Zhang Wen, Xia ShiHai, Bi Xun. Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J]. Journal of Clinical Hepatology, 2017, 33(12): 2355-2360. doi: 10.3969/j.issn.1001-5256.2017.12.020
[19]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.
[20]	Chen Xi, Liang Bing, Wang YiGe, Fan XiaoHong. The Analysis of The efficacy and risk factors in obesity with non-alcoholic fatty liver disease subjects treated with orlistat.[J]. Journal of Clinical Hepatology, 2006, 22(2): 123-124.

Supplements(0)

Cited By

Cited by

Periodical cited type(17)

1.	杨文帅，王立坤，董聪慧，武永萍，石栓柱. 瞬时弹性成像技术联合血清游离脂肪酸对非酒精性脂肪性肝病的诊断价值. 转化医学杂志. 2024(09): 1330-1335 .
2.	崔会鹏，田昊宇，关琳，李异玲. 代谢相关性脂肪性肝病无创诊断方法研究进展. 胃肠病学和肝病学杂志. 2022(01): 99-103 .
3.	凡军芳，胡静，耿旭，庄兰艮，时照明. 2型糖尿病患者肝脏受控衰减参数与血清25-羟维生素D的相关性. 中华全科医学. 2021(05): 794-797 .
4.	陈雅洁，李昭贤，王洋，曹经琳，窦剑. 瞬时弹性成像技术在肝移植围手术期应用的研究进展. 中华器官移植杂志. 2021(08): 501-504 .
5.	林俊红，林常青，翁娜，刘宴伟. 中年女性高血压体检者体质指数异常与脂肪肝发病率的相关性研究及护理干预. 全科护理. 2020(10): 1212-1214 .
6.	张晓静，林淑珍，张志安，温美兰. FibroTouch技术在诊断非酒精性脂肪性肝病患者肝脂肪变程度中的应用. 临床医学. 2020(04): 79-80 .
7.	李萍英，李娟，谢守珍，杨永耿，陆伦根. FibroTouch联合超声和CT检查诊断高原地区非酒精性脂肪性肝病临床应用研究. 实用肝脏病杂志. 2020(06): 817-820 .
8.	李正鑫，陈洋溢，赵志敏，吕靖，陈高峰，刘成海. 基于肝脏病理学对慢性乙型肝炎肝硬化患者FibroTouch测量值的影响因素分析. 临床肝胆病杂志. 2019(02): 338-344 . 本站查看
9.	陈中淑. 超声检查在诊断脂肪肝方面的临床应用价值. 当代医药论丛. 2019(10): 26-28 .
10.	何义华，罗建君，文安怡，程志生，余志映，吴舒婷. 二至解酲汤治疗酒精性肝病临床研究. 中医学报. 2018(06): 1099-1102 .
11.	何妙峰. 腹部B超对健康体检者脂肪肝筛查的价值分析. 深圳中西医结合杂志. 2018(10): 90-91 .
12.	王晴晴，胡明芬，杨红洁，禹蔚琴，柏保利，匡小林，庄林. B超在慢性HBV携带者合并非酒精性脂肪性肝病诊断中的应用. 肝脏. 2018(08): 723-727 .
13.	王新. 脂肪肝与病毒性肝炎B超鉴别诊断结果的对比研究. 心理月刊. 2018(04): 47-48 .
14.	张志伟. 肝功能与血清学指标水平检验对脂肪肝的诊断价值分析. 中外医疗. 2018(34): 11-13 .
15.	南胜天. CT及B超在脂肪肝临床诊断中应用的价值. 甘肃科技. 2017(07): 102-103 .
16.	庄小芳，孙洁，王晓波，王燕，吴琦琦，王晓忠. 瞬时弹性成像技术诊断非酒精性脂肪性肝病的性能评估. 临床肝胆病杂志. 2017(12): 2366-2371 . 本站查看
17.	杨杰，曹玉芝，徐永升，王雪，刘闯. 373例非酒精性脂肪性肝病FibroTouch检测临床观察. 中国实用医药. 2017(24): 33-34 .

Other cited types(12)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1726) PDF downloads(276)

Value of liver stiffness measurement in the diagnosis of liver fibrosis degree in HBeAg-positive patients with chronic HBV infection

DOI: 10.3969/j.issn.1001-5256.2019.06.016